Regulatory review for the CagriSema combination therapy is ongoing
A very rare, inherited disorder, cTTP is caused by a disease-causing mutation in the ADAMTS13 gene, which is responsible for making the ADAMTS13 enzyme that regulates blood clotting
It is important to highlight that the only legal path runs through licensed pharmacies, valid prescriptions, and FDA-permitted compounds
The effects of BPC-157 on HUVECs might be mediated by activation of ERK1/2 phosphorylation, leading to enhanced cell proliferation, migration, and tube formation
The peptide appears to have analgesic effects that are produced through increased levels of the natural painkiller L-lysine [12]
Several studies, including clinical trials, suggest its potential role in combating COVID-19 and other health conditions